Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) plunged 80% on Monday following publication of final results from the COMPANION-002 Phase 2/3 trial evaluating tovecimig in patients with biliary tract cancer.
Tovecimig, described by the company as a DLL4 x VEGF-A bispecific antibody, was tested in combination with paclitaxel. The combination produced a median progression-free survival (PFS) of 4.7 months compared with 2.6 months for paclitaxel alone, representing a 56% reduction in the risk of progression (hazard ratio = 0.44, p < 0.001). The regimen previously met the study's primary endpoint of overall response rate (ORR), posting 17.1% versus 5.3% for paclitaxel alone (p = 0.031).
Despite these positive signals on PFS and ORR, the trial did not meet statistical significance for overall survival (OS), a key secondary endpoint. The OS analysis was affected by substantial crossover: 54% of patients randomized to the control arm later received tovecimig. Median OS was 8.9 months for patients on the tovecimig plus paclitaxel arm and 9.4 months for the control arm (HR = 1.05, p = 0.78).
In a subset analysis confined to control-arm patients, those who crossed over to tovecimig had a median OS of 12.8 months compared with 6.1 months for patients who did not cross over (HR = 0.54, p = 0.04). Across the study population, 85% of patients received tovecimig at some point, yielding a pooled median OS of 8.9 months.
The safety profile in the tovecimig combination arm included commonly observed treatment-emergent adverse events of hypertension (69%) and fatigue (67%). Grade 3 or higher adverse events considered related to treatment included hypertension (44%) and neutropenia (36%).
Compass said it intends to meet with the U.S. Food and Drug Administration in advance of a planned Biologics License Application submission for tovecimig. The company highlighted the patient population: biliary tract cancer affects approximately 26,500 patients annually in the United States, and there is no FDA-approved second-line treatment for patients without actionable mutations.
The mixed efficacy findings - improvement in PFS and ORR but no statistically significant OS benefit in the primary analysis - and the high rate of control-arm crossover framed investor reaction and the steep sell-off in Compass stock.
Summary
Compass reported that tovecimig plus paclitaxel improved progression-free survival and overall response rate in COMPANION-002, but the trial failed to show an OS benefit in the main analysis, a result complicated by extensive crossover from the control arm. The announcement coincided with an 80% drop in the company's share price.
Key points
- Tovecimig plus paclitaxel achieved median PFS of 4.7 months versus 2.6 months for paclitaxel alone (HR = 0.44, p < 0.001) and met the primary ORR endpoint (17.1% vs 5.3%, p = 0.031).
- The study did not meet statistical significance for OS in the primary analysis (median OS 8.9 months vs 9.4 months; HR = 1.05, p = 0.78), with 54% of control-arm patients crossing over to receive tovecimig.
- Safety signals included hypertension and fatigue as the most common treatment-emergent events; grade 3+ related events included hypertension (44%) and neutropenia (36%).
Risks and uncertainties
- Overall survival analysis was confounded by high crossover (54% of control-arm patients received tovecimig), which complicates interpretation of OS outcomes - impacting regulatory assessment and investor confidence in the biotech and healthcare sectors.
- Notable treatment-related toxicities, including high rates of hypertension and neutropenia, present safety risks that could affect clinical adoption and payer decisions - relevant to pharmaceutical and healthcare services sectors.
- Regulatory uncertainty remains ahead of the planned BLA submission and the company's meeting with the FDA, which could influence the drug's approval prospects and the broader small-cap biotech equity market.